---
document_datetime: 2024-09-13 10:05:26
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/byooviz-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: byooviz-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.9589055
conversion_datetime: 2025-12-22 18:05:01.935755
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Byooviz

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0019               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 12/09/2024                          |                                             | PL                               |           |
| IB/0018/G            | This was an application for a group of variations.                                               | 22/05/2024                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|        | product - Other changes to a test procedure (including replacement or addition) B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                  |            |     |    |                     |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|---------------------|
| N/0017 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                              | 19/04/2024 |     | PL |                     |
|        | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other | 07/02/2024 | n/a |    | IB/0015/G variation |
| N/0014 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                              | 11/01/2024 |     | PL |                     |
|        | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing                                                                                           | 05/10/2023 | n/a |    | II/0012/G           |

<div style=\"page-break-after: always\"></div>

|                    | process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product                                                                                                                                    |            |            |             |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| IA/0013            | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                         | 02/08/2023 | n/a        |             |                                   |
| PSUSA/2609/ 202210 | Periodic Safety Update EU Single assessment - ranibizumab                                                                                                                                                                                            | 12/05/2023 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0010            | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                             | 21/02/2023 | 07/12/2023 | SmPC and PL |                                   |
| IA/0011            | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                  | 16/01/2023 | n/a        |             |                                   |
| IB/0007            | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                  | 04/01/2023 | 07/12/2023 | SmPC        |                                   |
| IA/0008            | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                              | 16/12/2022 | n/a        |             |                                   |
| IB/0006            | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 15/12/2022 | 07/12/2023 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

|           | the MAH                                                                                                                                                                                            |            |            |                        |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IB/0005   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                      | 10/11/2022 | n/a        |                        |
| IB/0004   | B.I.z - Quality change - Active substance - Other variation                                                                                                                                        | 05/10/2022 | n/a        |                        |
| IB/0003   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                | 11/04/2022 | 29/09/2022 | SmPC                   |
| IAIN/0002 | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 12/10/2021 | 29/09/2022 | SmPC, Labelling and PL |